PIK3CA mutations in advanced cancers: characteristics and outcomes. - Wikidata - awgldk - TriplyDB

PIK3CA mutations in advanced cancers: characteristics and outcomes.

PIK3CA mutations in advanced cancers: characteristics and outcomes.

http://www.wikidata.org/entity/Q36926111

about

DAB2IP in cancer Emerging targeted therapies for melanoma treatment (review)From single-gene to multiplex analysis in lung cancer, challenges and accomplishments: a review of a single institution's experience.NF2/merlin in hereditary neurofibromatosis 2 versus cancer: biologic mechanisms and clinical associations.Unique molecular signatures as a hallmark of patients with metastatic breast cancer: implications for current treatment paradigms Pilot study of sirolimus in patients with PIK3CA mutant/amplified refractory solid cancer.PIK3CA gene mutations and overexpression: implications for prognostic biomarker and therapeutic target in Chinese esophageal squamous cell carcinoma.TOR-centric view on insulin resistance and diabetic complications: perspective for endocrinologists and gerontologists.Selective anti-cancer agents as anti-aging drugs Activation of diverse signalling pathways by oncogenic PIK3CA mutations.PIK3CA mutations frequently coexist with EGFR/KRAS mutations in non-small cell lung cancer and suggest poor prognosis in EGFR/KRAS wildtype subgroup Molecularly targeted therapies in non-small-cell lung cancer annual update 2014 Assessing PIK3CA and PTEN in early-phase trials with PI3K/AKT/mTOR inhibitors.Epidermal growth factor receptor pathway mutation and expression profiles in cervical squamous cell carcinoma: therapeutic implications.KRAS and KIT Gatekeeper Mutations Confer Polyclonal Primary Imatinib Resistance in GI Stromal Tumors: Relevance of Concomitant Phosphatidylinositol 3-Kinase/AKT Dysregulation.Cyclin-dependent kinase pathway aberrations in diverse malignancies: clinical and molecular characteristics.Potential impact of mTOR inhibitors on cervical squamous cell carcinoma: A systematic review.Mutually exclusive mutations in NOTCH1 and PIK3CA associated with clinical prognosis and chemotherapy responses of esophageal squamous cell carcinoma in China.Advances and Concepts in Cervical Cancer Trials: A Road Map for the Future.Efemp1 and p27(Kip1) modulate responsiveness of pancreatic cancer cells towards a dual PI3K/mTOR inhibitor in preclinical models.Challenges in initiating and conducting personalized cancer therapy trials: perspectives from WINTHER, a Worldwide Innovative Network (WIN) Consortium trial.Dietary restriction-resistant human tumors harboring the PIK3CA-activating mutation H1047R are sensitive to metformin CDK4/6-inhibiting drug substitutes for p21 and p16 in senescence: duration of cell cycle arrest and MTOR activity determine geroconversion.Dysregulation of the mTOR pathway in p53-deficient mice.Computational drugs repositioning identifies inhibitors of oncogenic PI3K/AKT/P70S6K-dependent pathways among FDA-approved compounds.Exome Sequencing Identifies Potentially Druggable Mutations in Nasopharyngeal Carcinoma.Targeting PI3K in Cancer: Any Good News?Novel treatments for head and neck squamous cell carcinoma: preclinical identification and clinical investigation.BYL719, a new α-specific PI3K inhibitor: single administration and in combination with conventional chemotherapy for the treatment of osteosarcoma.Oncogenic KRAS sensitizes premalignant, but not malignant cells, to Noxa-dependent apoptosis through the activation of the MEK/ERK pathway.Immunosuppressants in cancer prevention and therapy Bringing target-matched PI3King from the bench to the clinic.Comparative molecular analyses of left-sided colon, right-sided colon, and rectal cancers.Herbacetin suppresses cutaneous squamous cell carcinoma and melanoma cell growth by targeting AKT and ODC.Comprehensive genomic profiles of metastatic and relapsed salivary gland carcinomas are associated with tumor type and reveal new routes to targeted therapies.A Phase I Trial of the PI3K Inhibitor Buparlisib Combined With Capecitabine in Patients With Metastatic Breast Cancer.Unraveling the etiology of primary malignant melanoma of the esophagus.Insights into the mechanism of the PIK3CA E545K activating mutation using MD simulations

P2860

Q26776456-75E5C7E2-0732-4059-9F11-658496271960 Q26829997-7437BEFC-7305-4DD1-860A-CEB1AF984B21 Q28385559-FFBC4A5F-4864-42FB-9C01-25D4B2C739EC Q30440530-E26DAB3F-E903-4219-A932-2DA35AF2C253 Q33756991-5297C98F-E9C8-4D77-B177-39E510B54CF0 Q33858387-1021E092-9E43-4D1E-BD28-602924B79635 Q33940350-44535425-9B7F-4C51-BF68-B974AA746A69 Q34391710-E7D6A981-5237-47C9-AE64-8B9595521645 Q34392470-766075E8-D3BA-4309-ABD6-B5B96582C69B Q34408364-781382B0-7FE4-4A73-849E-F59626458C4E Q35095308-2D990DF0-76EE-4BA8-8384-2A49480BACFD Q35136424-3D7AC835-E1CA-4CEA-B133-474D6FFE1BBC Q35535953-02888CDC-78F4-4F23-930F-ED17C771942D Q35885555-09F20C53-8AE5-42F8-873E-2B1E0A149F87 Q36025994-CC215E5B-BA14-4E3A-9615-EC1FCAF1020E Q36188947-9A12F724-0AE2-41D9-AFA6-034B8D9D81C9 Q36206239-9E15BC79-DEB1-4E3A-8B20-B9DB5FB3D693 Q36772217-59FB761B-EBE9-4DEE-BFC5-1CC416F4CA7B Q36796568-3BA6FD23-5F70-4D2B-9413-F0A15C1F8E2C Q37016570-D4064B2A-C16E-4D4A-BFBC-09C38A9CD401 Q37220383-E9A3A238-1548-46EB-AE3A-A3F884E34592 Q37299288-630F3614-256F-4337-A4C5-19B1E3F5D577 Q37420058-256A59A7-7169-45B5-83D2-A7A37E29EAE0 Q37548879-4B73AE68-839C-496E-BA96-75EC64B0E2F1 Q37644761-A4E79B4A-CE5E-44AD-A67C-F6C109DF3BB4 Q37678950-429CB79C-F721-4C84-821B-80C5FFD45F20 Q38105322-D0F77A32-E316-4562-8C1D-0189E240AB6A Q38221292-2944759D-ABF7-48C6-86DB-13380ED6896E Q38981617-97DB5EF4-514C-49F7-AE1D-3BB66F1E35C7 Q41627000-F34A7239-3CAA-43BD-8760-E9F20CF629D9 Q42505783-2913A2E2-91E3-480D-804D-7107F5FAB47C Q42541269-70962F0F-6183-4ED9-8972-D5BF6E112D26 Q46185591-87F61FAB-B8B6-4A71-AF21-8915BEFE2D74 Q47613853-10912F89-691A-4977-8167-032E7229BC3A Q47923316-4A4041B1-F2A3-4234-8985-387417E1B271 Q49886531-B756CE86-CBF1-41FF-8407-7E8ACA0EE231 Q55075049-8D595224-ACBC-4C7E-B355-1B359C876603 Q57811390-31A5041F-BDD5-4A1A-9D72-40F53ED1CE21

P2860

PIK3CA mutations in advanced cancers: characteristics and outcomes.

http://www.wikidata.org/entity/Q36926111

description

2012 nî lūn-bûn

@nan

2012年の論文

@ja

2012年論文

@yue

2012年論文

@zh-hant

2012年論文

@zh-hk

2012年論文

@zh-mo

2012年論文

@zh-tw

2012年论文

@wuu

2012年论文

@zh

2012年论文

@zh-cn

name

PIK3CA mutations in advanced cancers: characteristics and outcomes.

@en

type

label

PIK3CA mutations in advanced cancers: characteristics and outcomes.

@en

prefLabel

PIK3CA mutations in advanced cancers: characteristics and outcomes.

@en

P1433

Q36926111-4F00DF90-51C3-447C-B104-D4072882F49B

P1476

Q36926111-9809211A-D972-4D17-A6BF-C2520FCEE31B

P2093

Q36926111-28DC2A07-51D8-468C-B6E1-AD8176921FCB

Q36926111-2DFDB69D-2220-4903-8479-19BFC77E6D49

Q36926111-55E4E27E-E2B2-439C-B46B-496FFBE9B37A

Q36926111-82C265F2-DEEE-4E73-B2AB-DED42F2C24AE

Q36926111-A0F8619B-465B-441E-8A05-B5EAE9E8FFEE

Q36926111-BAFC382B-1F23-4831-8171-F4CAF871CE44

Q36926111-C4B375D6-DE8A-48AB-ACB2-6838736D7D44

Q36926111-F140D66A-6418-40FB-A9EC-E33D8C4B21C6

Q36926111-FA9F66F5-E7DF-4030-97DF-113A4D5AEF97

P2860

Q36926111-013A1BEA-1CA0-481A-981C-EEF12BC369E1

Q36926111-13CD2B7A-CF6E-43C4-B197-251711DC024D

Q36926111-187D9C0A-C7A0-4B5C-828F-09C6CDA00C30

Q36926111-1C22F1FC-2645-4F34-AC2E-28C9DB584308

Q36926111-2ABD78AE-0E6E-478F-8D83-E13551B8C1C1

Q36926111-2C78C3DF-A2ED-4EEA-A11C-E9CBE04A866E

Q36926111-42B27C7E-0339-41F4-917D-0E9F5A22BFC7

Q36926111-49DDBA81-1174-403F-BEFF-AD90B97CEBE0

Q36926111-539302DA-91B5-4D62-BA6F-1BC37D4213AE

Q36926111-5655DA98-9483-418F-BEF0-48BA0B48FDFD

P304

Q36926111-FDD20380-07B0-4D33-A4D4-5632ED5CEC62

P31

Q36926111-77E08837-9D96-4C1F-97C5-34E0156E6B04

P356

Q36926111-951D56EB-17C6-433D-A30B-C6074AF7C9DA

P407

Q36926111-07778301-74E2-4ACE-9867-5F3F4F94B9B1

P433

Q36926111-91B1BBB7-C0A2-4217-80CE-58F5CA3932C7

P478

Q36926111-01E775A7-B457-4028-900F-B5C6DFE8D8EF

P50

Q36926111-0716DE45-0FC4-4521-9706-89B8983BB34B

Q36926111-1DDBDC3B-123C-4D13-A620-5DBDC9F369E3

Q36926111-C47A242C-9C72-45C1-84EB-B33F0C68AFF0

Q36926111-F1189518-1C21-4915-9F75-8DCFC9F57719

Q36926111-F84A8650-F336-41C5-87A5-10CEFD3ACCB6

P577

Q36926111-A05FEF37-411E-4C3C-A3CA-1B983415F50E

P5875

Q36926111-F358DA5A-1369-4C5E-8CDE-CBD03CC33FE0

P698

Q36926111-128A35E1-0E30-4F5A-876A-18977683641B

P932

Q36926111-F87E576C-F2CC-4221-B998-FC5167F7E7EB

P356

P1433

P1476

PIK3CA mutations in advanced cancers: characteristics and outcomes.

@en

P2093

David S Hong

http://www.w3.org/2001/XMLSchema#string

Gerald S Falchook

http://www.w3.org/2001/XMLSchema#string

Jack J Lee

http://www.w3.org/2001/XMLSchema#string

Jennifer J Wheler

http://www.w3.org/2001/XMLSchema#string

Rajyalakshmi Luthra

http://www.w3.org/2001/XMLSchema#string

Sarina A Piha-Paul

http://www.w3.org/2001/XMLSchema#string

Siqing Fu

http://www.w3.org/2001/XMLSchema#string

Stacy L Moulder

http://www.w3.org/2001/XMLSchema#string

Vanda M Stepanek

http://www.w3.org/2001/XMLSchema#string

P2860

Deregulation of the PI3K and KRAS signaling pathways in human cancer cells determines their response to everolimus

Phosphatidylinositol 3-kinase and antiestrogen resistance in breast cancer

Effective use of PI3K and MEK inhibitors to treat mutant Kras G12D and PIK3CA H1047R murine lung cancers.

Effects of KRAS, BRAF, NRAS, and PIK3CA mutations on the efficacy of cetuximab plus chemotherapy in chemotherapy-refractory metastatic colorectal cancer: a retrospective consortium analysis.

Anaplastic lymphoma kinase inhibition in non-small-cell lung cancer.

Inhibition of Mutated, Activated BRAF in Metastatic Melanoma

New guidelines to evaluate the response to treatment in solid tumors. European Organization for Research and Treatment of Cancer, National Cancer Institute of the United States, National Cancer Institute of Canada

BRAF mutations in advanced cancers: clinical characteristics and outcomes

Gefitinib or chemotherapy for non-small-cell lung cancer with mutated EGFR

Targeting PI3K signalling in cancer: opportunities, challenges and limitations

P304

1566-1575

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.18632/ONCOTARGET.716

http://www.w3.org/2001/XMLSchema#string

P407

P433

12

http://www.w3.org/2001/XMLSchema#string

P478

3

http://www.w3.org/2001/XMLSchema#string

P50

Razelle Kurzrock

Apostolia Maria Tsimberidou

Ignacio Garrido-Laguna

P577

2012-12-01T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P5875

233941818

http://www.w3.org/2001/XMLSchema#string

P698

23248156

http://www.w3.org/2001/XMLSchema#string

P932

3681495

http://www.w3.org/2001/XMLSchema#string